When faced with a threat, T cells have the decision-making flexibility to both clear out the pathogen now and ready themselves for a future encounter.
Academic rigour, journalistic flair
Articles on T cells
Displaying 1 - 20 of 49 articles
Dietary supplements claim to be able to ‘boost your immune system’ to combat disease. But attaining immune balance through a healthy lifestyle and vaccination is a safer bet to keep in good health.
T cells recognize and kill cancer cells but quickly lose their effectiveness. This fast dysfunction may help explain why immunotherapy doesn’t lead to long-term remission for many patients.
Researchers found that people with a specific gene variant were two to eight times more likely to not have symptoms after infection.
Certain immune cells acquired from a coronavirus that causes the common cold appear to react to COVID – but more so in children that adults.
Preventive and therapeutic vaccines both train the immune system to fight disease, but they are used in different ways.
Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.
Inflammation is a complicated and important part of how the immune system responds to threats to the body. But when the inflammatory response goes awry, it can lead to serious problems.
German doctors have reported success in treating patients with severe lupus, using cell treatments like those used for some forms of blood cancer.
Evidence is growing there are changes to your immune system that may put you at risk of other infectious diseases.
Patients with blood cancer undergoing stem cell transplantation have a high risk of complications. The bacteria in their gut, however, can help their immune system recover and fight infections.
While the immune system naturally gets weaker with age, social stressors like trauma and discrimination can hasten immunosenescence.
One promising cancer treatment has been in the works for decades, but severe side effects have kept it out of the clinic. A reengineered version may offer a way to safely harness its potent effects.
Infection seems to add a boost to immunity – but vaccination is still vital and breakthrough infections should be avoided as much as possible.
Some of the omicron variant’s unique properties – such as its ability to spread rapidly while causing milder COVID-19 infections – could usher in a new phase of the pandemic.
DNA and mRNA vaccines produce a different kind of immune response than traditional vaccines, allowing researchers to tackle some previously unsolvable problems in medicine.
Having a range of immune cells that target different parts of the virus appears to make disease milder and could protect against future variants.
We won’t know whether Omicron evades COVID vaccines for another few weeks. Here’s why.
There’s not enough evidence yet to support the AstraZeneca CEO’s statement. But it is theoretically plausible.
But the immune cells that vaccination spurs do last a long time.
Top contributors
-
Professor in Immunology, University of Manchester
-
Senior Lecturer; MD, Victoria University
-
Professor of Immunology, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Assistant Professor of Immunology and Microbiology, University of Colorado Anschutz Medical Campus
-
Professor of Immunopharmacology, Queen Mary University of London
-
Professor of Immunology, University of Connecticut
-
Professor of Immunology and Director, Institute of Immunology and Immunotherapy, University of Birmingham
-
Assistant Professor of Biological Sciences, University of North Carolina – Charlotte
-
MD-Ph.D. Candidate in Molecular Pathology and Immunology, Vanderbilt University
-
Professor of Neurology, University of California, San Francisco
-
Lecturer in Immunology, University of Essex
-
Postdoctoral research scientist, Columbia University
